Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus
Open-label, no control groupHumansTopical
- Design
- Open-label, no control group
- Subjects
- 22 patients with prurigo, lichen simplex or other chronic itch
- Dose used in the study
- An emollient cream containing N-palmitoylethanolamine, applied by patients over the course of the study
- Duration
- Not stated in the abstract
- What was measured
- Antipruritic effect, judged as good or not, and the percentage reduction in itch.
What the authors reported
This open application study found:
- 14 of 22 patients (64%) had a good antipruritic effect.
- Itch fell by an average of 86.4% across the group.
- The cream was well tolerated by all patients, with no burning or contact dermatitis reported.
Limits of this study
Article in German; entry checked against the English abstract only. Open application with no control cream or placebo, in a small and mixed group of itch conditions (prurigo, lichen simplex and unspecified chronic pruritus), so results cannot be broken down by diagnosis. Duration and dosing frequency are not given in the abstract.
Source
PubMed 16874533 · doi:10.1007/s00105-006-1180-1
Entry checked against the English abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.